Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy

American Journal of Cardiology

Volumn 115, Issue 9, 2015, Pages 1305-1310

  Amsallem, Myriam ^a   Manzo Silberman, Stephane ^a   Dillinger, Jean Guillaume ^a   Sideris, Georgios ^a   Voicu, Sebastian ^a   Bal Dit Sollier, Claire ^a   Drouet, Ludovic ^a   Henry, Patrick ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ARACHIDONIC ACID; CLOPIDOGREL; COLLAGEN; FIBRINOGEN; LYSINE ACETYLSALICYLATE; PRASUGREL; TICAGRELOR; VON WILLEBRAND FACTOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PIPERAZINE DERIVATIVE; PURINERGIC P2Y RECEPTOR ANTAGONIST; THIOPHENE DERIVATIVE; TICLOPIDINE;

ADULT; ANGIOPLASTY; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; HIGH ON ASPIRIN PLATELET REACTIVITY; HIGH RISK PATIENT; HUMAN; ISCHEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PLATELET REACTIVITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE FUNCTION; AGED; ANALOGS AND DERIVATIVES; BLOOD; CEREBROVASCULAR DISORDERS; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; SECONDARY PREVENTION; THROMBOCYTE ACTIVATION;

ADENOSINE; AGED; ASPIRIN; CEREBROVASCULAR DISORDERS; CORONARY ARTERY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RETROSPECTIVE STUDIES; SECONDARY PREVENTION; THIOPHENES; TICLOPIDINE;

EID: 84927570328     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.02.012     Document Type: Article

References (20)

1. D. Aradi, R.F. Storey, A. Komócsi, D. Trenk, D. Gulba, R.G. Kiss, S. Husted, L. Bonello, D. Sibbing, J.P. Collet, and K. Hubert Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention Eur Heart J 35 2014 209 215
2. G.N. Levine, E.R. Bates, J.C. Blankenship, S.R. Bailey, J.A. Bittl, B. Cercek, C.E. Chambers, S.G. Ellis, R.A. Guyton, S.M. Hollenberg, U.N. Khot, R.A. Lange, L. Mauri, R. Mehran, I.D. Moussa, D. Mukherjee, B.K. Nallamothu, and H.H. Ting 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions Circulation 124 2011 574 651
3. P. Henry, A. Vermillet, B. Boval, C. Guyetand, T. Petroni, J.-G. Dillinger, G. Sideris, C. Bal dit Sollier, and L. Drouet 24-Hour time-dependent aspirin efficacy in patients with stable coronary artery disease Thromb Haemost 105 2011 336 344
4. J.-G. Dillinger, A. Drissa, G. Sideris, C. Bal dit Sollier, S. Voicu, S. Manzo Silberman, D. Logeart, L. Drouet, and P. Henry Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease Am Heart J 164 2012 600 601
5. K. Müller, S. Aichele, M. Herkommer, B. Bigalke, K. Stellos, P. Htun, S. Fateh-Moghadam, A.E. May, M. Flather, M. Gawaz, and T. Geisler Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease Atherosclerosis 213 2010 256 262
6. T. Geisler, K. Müller, S. Aichele, B. Bigalke, K. Stellos, P. Htun, E. Ninci, S. Fateh-Moghadam, A.E. May, and M. Gawaz Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions Clin Res Cardiol Off J Ger Card Soc 99 2010 743 752
7. T. Gremmel, T. Perkmann, D. Seidinger, R. Koppensteiner, S. Panzer, C.W. Kopp, and S. Steiner Differential impact of inflammation on six laboratory assays measuring residual arachidonic acid-inducible platelet reactivity during dual antiplatelet therapy J Atheroscler Thromb 20 2013 630 645
8. S.B. Larsen, E.L. Grove, S.D. Kristensen, and A.M. Hvas Reduced antiplatelet effect of aspirin is associated with low-grade inflammation in patients with coronary artery disease Thromb Haemost 109 2013 920 929
9. E.H.A.M. Elsenberg, J.W. van Werkum, R.M.A. van de Wal, A.C. Zomer, H.J. Bouman, F.W.A. Verheugt, J.M. Berg, and C.M. Hackeng The influence of clinical characteristics, laboratory and inflammatory markers on 'high on-treatment platelet reactivity' as measured with different platelet function tests Thromb Haemost 102 2009 719 727
10. A.-Å.R. Pettersen, H. Arnesen, T.B. Opstad, V. Bratseth, and I. Seljeflot Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease Thromb Res 130 2012 424 428
11. E.L. Grove, A.M. Hvas, S.B. Mortensen, S.B. Larsen, and S.D. Kristensen Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease J Thromb Haemost 9 2011 185 191
12. E.H. Awtry, and J. Loscalzo Aspirin Circulation 101 2000 1206 1218
13. C. Patrono, G. Ciabattoni, P. Patrignani, F. Pugliese, P. Filabozzi, F. Catella, G. Davi, and L. Forni Clinical pharmacology of platelet cyclooxygenase inhibition Circulation 72 1985 1177 1184
14. F. Cipollone, B. Rocca, and C. Patrono Cyclooxygenase-2 expression and inhibition in atherothrombosis Arterioscler Thromb Vasc Biol 24 2004 246 255
15. V. Evangelista, S. Manarini, A. Di Santo, M.L. Capone, E. Ricciotti, L. Di Francesco, S. Tacconelli, A. Sacchetti, S. D'Angelo, A. Scilimati, M.G. Sciulli, and P. Patrignani De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin Circ Res 98 2006 593 595
16. J.-G. Dillinger, G. Sideris, P. Henry, C. Bal dit Sollier, E. Ronez, and L. Drouet Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia Thromb Res 129 2012 91 94
17. F. Samad, and W. Ruf Inflammation, obesity, and thrombosis Blood 122 2013 3415 3422
18. T. Cuisset, C. Frere, J. Quilici, B. Gaborit, L. Bali, R. Poyet, D. Faille, P.E. Morange, M.-C. Alessi, and J.-L. Bonnet Aspirin noncompliance is the major cause of 'aspirin resistance' in patients undergoing coronary stenting Am Heart J 157 2009 889 893
19. M. Lordkipanidzé, C. Pharand, E. Schampaert, J. Turgeon, D.A. Palisaitis, and J.G. Diodati A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease Eur Heart J 28 2007 1702 1708
20. P.A. Gum, K. Kottke-Marchant, P.A. Welsh, J. White, and E.J. Topol A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 41 2003 961 965